Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T92687
|
||||
Target Name |
H+ K+ ATPase
|
||||
Target Type |
Successful
|
||||
Disease | Duodenal ulcers [ICD10: K25-K27] | ||||
Gastroesophageal reflux disease [ICD9: 140-229, 530; ICD10: K21] | |||||
Gastrointestinal disease [ICD10: K00-K93] | |||||
Nsaid-related gastric ulcer [ICD9: 531; ICD10: K25] | |||||
Peptic ulcer [ICD9: 531-534; ICD10: K25-K27] | |||||
Ulcerative colitis [ICD9: 556; ICD10: K51] | |||||
Unspecified [ICD code not available] | |||||
BioChemical Class |
Hydrolases (EC:3)
|
||||
UniProt ID | |||||
EC Number |
EC 3.6.3.10
|
||||
Drugs and Mode of Action | |||||
Drug(s) | Esomeprazole | Drug Info | Approved | Peptic ulcer | [536779], [540887] |
Lansoprazole | Drug Info | Approved | Peptic ulcer | [535862], [542222] | |
Omeprazole | Drug Info | Approved | Gastroesophageal reflux disease | [467616], [537527] | |
Pantoprazole | Drug Info | Approved | Gastroesophageal reflux disease | [535862], [542279] | |
Lansoprazole | Drug Info | Phase 3 | Nsaid-related gastric ulcer | [535862], [542222] | |
RQ-00000004 | Drug Info | Phase 3 | Gastroesophageal reflux disease | [549204] | |
TAK-438 | Drug Info | Phase 3 | Gastroesophageal reflux disease | [525119] | |
AZD-0865 | Drug Info | Phase 2 | Gastrointestinal disease | [521710] | |
S-tenatoprazole | Drug Info | Phase 2 | Peptic ulcer | [521790] | |
YH-4808 | Drug Info | Phase 2 | Duodenal ulcers | [523802] | |
LEMINOPRAZOLE | Drug Info | Discontinued in Preregistration | Ulcerative colitis | [544691] | |
PUMAPRAZOLE | Drug Info | Discontinued in Phase 3 | Duodenal ulcers | [545964] | |
SKF-96067 | Drug Info | Discontinued in Phase 3 | Peptic ulcer | [544818] | |
AR-H047108 | Drug Info | Discontinued in Phase 2 | Duodenal ulcers | [547136] | |
SORAPRAZAN | Drug Info | Discontinued in Phase 2 | Peptic ulcer | [547328] | |
TY-11345 | Drug Info | Discontinued in Phase 2 | Peptic ulcer | [544845] | |
CS-526 | Drug Info | Discontinued in Phase 1 | Gastroesophageal reflux disease | [547339] | |
SKF-97574 | Drug Info | Discontinued in Phase 1 | Peptic ulcer | [545026] | |
Saviprazole | Drug Info | Terminated | Peptic ulcer | [544684] | |
SK&F-95601 | Drug Info | Terminated | Peptic ulcer | [544683] | |
Modulator | AR-H047108 | Drug Info | |||
AZD-0865 | Drug Info | [528510] | |||
CS-526 | Drug Info | [528949] | |||
Esomeprazole | Drug Info | [556264] | |||
Lansoprazole | Drug Info | [556264] | |||
LEMINOPRAZOLE | Drug Info | ||||
Omeprazole | Drug Info | [556264] | |||
Pantoprazole | Drug Info | [556264] | |||
PUMAPRAZOLE | Drug Info | ||||
RQ-00000004 | Drug Info | [529788] | |||
S-tenatoprazole | Drug Info | ||||
Saviprazole | Drug Info | [528168] | |||
SK&F-95601 | Drug Info | ||||
SKF-96067 | Drug Info | [1572591] | |||
SKF-97574 | Drug Info | [1572591] | |||
SORAPRAZAN | Drug Info | ||||
TAK-438 | Drug Info | ||||
TY-11345 | Drug Info | [533944] | |||
YH-1238 | Drug Info | ||||
YH-4808 | Drug Info | ||||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
References | |||||
Ref 467616 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4279). | ||||
Ref 521710 | ClinicalTrials.gov (NCT00206284) A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.. U.S. National Institutes of Health. | ||||
Ref 521790 | ClinicalTrials.gov (NCT00282555) Efficiency Study of S-Tenatoprazole-Na to Treat Erosive or Ulcerative Esophagitis. U.S. National Institutes of Health. | ||||
Ref 523802 | ClinicalTrials.gov (NCT01538849) Study to Investigate the Safety, Tolerability and Efficacy of YH4808 in Patients With Reflux Esophagitis. U.S. National Institutes of Health. | ||||
Ref 525119 | ClinicalTrials.gov (NCT02388724) Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Patients With Erosive Esophagitis. U.S. National Institutes of Health. | ||||
Ref 536779 | Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults. Drugs. 2008;68(11):1571-607. | ||||
Ref 537527 | Generic omeprazole delayed-release capsules: in vitro performance evaluations. Drug Dev Ind Pharm. 2009 Aug;35(8):917-21. | ||||
Ref 540887 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5488). | ||||
Ref 542222 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7208). | ||||
Ref 542279 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7260). | ||||
Ref 544683 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000578) | ||||
Ref 544684 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000579) | ||||
Ref 544691 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000604) | ||||
Ref 544818 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001218) | ||||
Ref 544845 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001313) | ||||
Ref 545026 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001921) | ||||
Ref 545964 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005537) | ||||
Ref 547136 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013302) | ||||
Ref 547328 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015211) | ||||
Ref 528168 | Gastric acid inhibitory profile of saviprazole (HOE 731) compared to omeprazole. Pharmacology. 1991;43(6):293-303. | ||||
Ref 528510 | Mechanism of action of AZD0865, a K+-competitive inhibitor of gastric H+,K+-ATPase. Biochem Pharmacol. 2007 Jan 15;73(2):198-205. Epub 2006 Sep 24. | ||||
Ref 528949 | Pharmacological profile of novel acid pump antagonist 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methyl cyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526). J Pharmacol Exp Ther. 2007 Oct;323(1):308-17. Epub 2007 Jul 13. | ||||
Ref 529788 | N-(2-hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-chromen-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide (PF-03716556), a novel, potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux disease. J Pharmacol Exp Ther. 2009 Feb;328(2):671-9. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.